Advanced gastric cancer with serosal invasion is usually unresectable, so anticancer drugs are infused intravenously as a palliative treatment; however, patients with unresectable gastric cancer die within a few months after exploration, with or without palliative surgery. 5-Fluorouracil (5-FU) is the cornerstone chemotherapy regimen for gastric cancer, having mild to moderate toxicity and response rate.
Stomach-and Site-Selective Delivery of 5-Fluorouracil Following Its Application on the Gastric Serosal Surface in Rats
The present study was undertaken to elucidate the stomach-and site-selective delivery of 5-fluorouracil (5-FU) following its application on the gastric serosal surface in rats. An experimental system utilizing a cylindrical diffusion cell attached to the gastric serosal surface was established. To evaluate the gastric distribution of 5-FU, the stomach was separated into the site under the diffusion cell (site 1) and the site not under the diffusion cell (site 2). Furthermore, the mucosal side at site 1 was separated from the serosal side. After intravenous and oral administration of 5-FU, the 5-FU concentrations at sites 1 and 2 until 240 min were similar. After gastric serosal surface application of 5-FU, however, the concentration of 5-FU at site 1 until 240 min was approximately 10-fold higher than that at site 2, and was sustained. Furthermore, the 5-FU concentration on the mucosal side at site 1 and the serosal side at site 1 were comparable after gastric serosal surface application. The blood concentration of 5-FU was low (Ͻ4.4 m mg/ml) until 240 min after gastric serosal surface application. The maximum blood concentration of 5-FU after gastric serosal surface application was significantly lower than after intravenous administration. Thus, the stomach-and site-selective delivery system following application on the gastric serosal surface could be applied with anticancer drugs for the treatment of gastric cancer.
5-FU Assay Procedures in Blood and Tissues
The concentration of 5-FU in each tissue homogenate or blood sample was determined by the reported method with slight modification. 7) Briefly, the tissue homogenates (300 ml) and blood samples (300 ml) were added to a solution of 5-bromouracil (20 mg/ml, 150 ml) dissolved in isotonic phosphate buffer (pH 7.4) as an internal standard, 1 M sodium acetate buffer (pH 4.8, 100 ml), and 20% anhydrous sodium sulfate solution (500 ml). The mixtures were shaken with ethyl acetate (4 ml) for 10 min and centrifuged at 900ϫg for 10 min. The organic layers (3 ml) were collected. Then, ethyl acetate (4 ml) was added to the residue and the mixtures were shaken for 10 min, and thereafter centrifuged at 900ϫg for 10 min. The organic layers (4 ml) were collected and the mixed organic layers (7 ml) were evaporated. The extraction residues were dissolved in 500 ml of distilled water and were washed twice with 1.0 ml of hexane. Samples (100 ml) were injected onto the HPLC column. The recovery rates for the extraction of 5-FU from blood and each tissue homogenate were approximately 75%. The detection limits of 5-FU in the blood and each tissue homogenate were 0.2 mg/ml. An HPLC system (LC-6A, Shimadzu Co., Ltd., Kyoto, Japan) with a variablewavelength UV detector (SPD-10A, Shimadzu) was used in reverse-phase mode. The detector wavelength, flow rate, and column temperature were set at 266 nm, 0.5 ml/min, and 25°C, respectively. The mobile phase consisted of 10 mM sodium acetate buffer (pH 4.0). The stationary phase used was a Cosmosil 5C 18 -MS-II packed column (150 mm length ϫ4.6 mm i.d. connected with 150 mm lengthϫ4.6 mm i.d., Nacalai Tesque, Inc.).
Elimination of 5-FU from the Stomach after the Removal of 5-FU in the Diffusion Cell The rats were anesthetized with sodium pentobarbital. After the peritoneum was cut open, the cylindrical diffusion cell was attached to the gastric serosal surface, and 5-FU (10 mg/mlϫ0.5 ml, isotonic phosphate-buffered saline, pH 7.4) was added directly to the cylindrical diffusion cell. After 120 min, 5-FU was removed from the cylindrical diffusion cell and the gastric serosal surface in the diffusion cell was washed by saline (0.5 ml) 3 times. At 15 and 30 min after the removal of 5-FU, the rats were sacrificed, and the stomach was removed. The stomach was separated into the site under the diffusion cell (site 1) and the site not under the diffusion cell (site 2). The tissues were weighed and homogenized in isotonic phosphatebuffered saline, pH 7.4.
RESULTS

Absorption of 5-FU from the Gastric Serosal Surface
We established an experimental system utilizing a cylindrical diffusion cell attached to the gastric serosal surface in rats (Chart 1). This system enables us to examine the drug absorption from the gastric serosal surface without interference by absorption from the other organs and sites. 5) We examined the absorption characteristics of 5-FU following its application on the gastric serosal surface until 240 min at doses of 0.1, 1.0, and 5.0 mg in rats (Fig. 1) . After the gastric serosal surface application of 5-FU, 5-FU was absorbed approximately 60% in 240 min at each dose. A semi-log plot of the remaining amount of 5-FU in the diffusion cell gave a straight line, indicating that the absorption of 5-FU from the gastric serosal surface proceeds via a first-order process. The absorption rate constant K a of 5-FU from the gastric serosal surface at doses of 0.1, 1.0, and 5.0 mg was calculated to be 0.00413Ϯ0.00033, 0.00435Ϯ0.00022, and 0.00388Ϯ0.00029 min Ϫ1 , respectively, and there was no significant difference (one-way analysis of variance). From these results, it is suggested that the absorption of 5-FU from the gastric serosal surface is explained mostly by passive diffusion. Figure 2 shows the gastric concentration profiles of 5-FU until 240 min after intravenous administration (A), oral administration (B), and gastric serosal surface application (C) of 5-FU. After intravenous and oral administration of 5-FU, the concentrations of (Figs. 2A, B) . After the gastric serosal surface application of 5-FU, on the other hand, the concentration of 5-FU at site 1 was approximately 10-fold higher than at site 2, and was sustained for 240 min (Fig. 2C) . The 5-FU concentrations on the mucosal and serosal side in the stomach following intravenous and oral administration were not determined.
Gastric Distribution of 5-FU
Systemic Distribution of 5-FU The blood concentration profiles of 5-FU after intravenous administration (A), oral administration (B), and gastric serosal surface application (C) were evaluated (Fig. 3) . After oral administration and gastric serosal surface application of 5-FU, a low blood concentration (Ͻ4.4 mg/ml) was seen until 240 min. The maximum blood concentration after the oral administration and gastric serosal surface application was significantly lower than after intravenous administration. Figure 4 shows the concentration profiles of 5-FU in the stomach (site 1 and site 2), small intestine, liver, kidney, and heart until 240 min after intravenous administration (A), oral administration (B), and gastric serosal surface application (C) of 5-FU. The gastric concentrations of 5-FU after intravenous and oral administration are shown as the whole stomach because the 5-FU concentrations at site 1 and site 2 were similar (Fig. 2) . After intravenous administration of 5-FU, 5-FU was mainly distributed in the kidney, and this gastric concentration of 5-FU was much lower than that of the other administration routes (Fig. 4A) . After oral administration of 5-FU, 5-FU was mainly distributed in the stomach, but was rapidly eliminated from the stomach (Fig. 4B) . In contrast, after gastric serosal surface application of 5-FU, the concentration of 5-FU at site 1 was 10-fold higher than the concentration at site 2 and in other tissues (Fig. 4C) .
Elimination of 5-FU from the Stomach after the Removal of 5-FU in the Diffusion Cell Figure 5 shows the remaining 5-FU concentration until 30 min at site 1 and site 2 after the removal of 5-FU after gastric serosal surface application for 120 min. The rapid elimination of 5-FU from site 1 was observed.
Gastric Distribution at the Serosal and Mucosal Sides of Site 1 Figure 6 shows the gastric distribution of 5-FU until 240 min after the gastric serosal surface application of 5-FU. To evaluate the longitudinal distribution of 5-FU at site 1, the mucosal side was separated from the serosal side (Chart 2). After the gastric serosal surface application of 5-FU, 5-FU concentrations on the mucosal and serosal side at site 1 were from 8 to 27-fold higher than those at site 2. Furthermore, the 5-FU concentrations on the mucosal and serosal side at site 1 were comparable.
DISCUSSION
Gastric cancer still represents one of the most challenging therapeutic problems. Although diagnostic and technological advances have improved perioperative care, gastric cancer remains the leading cause of death from malignant disease. 1, 8) For effective therapy with medication, it is necessary to deliver anticancer drugs selectively to their target sites, since most anticancer drugs are associated with both beneficial effects and unfavorable actions. Also, it is important to elucidate the absorption mechanism of an anticancer drug following the intraperitoneal administration in cancer chemotherapy.
Gastric cancer is generated in the gastric mucosal side and then invades the gastric serosal side. 9) For effective chemotherapy of gastric cancer, therefore, a promising approach is to deliver the 5-FU to the mucosa following application on the gastric serosal surface. After the gastric serosal surface application of 5-FU, the 5-FU concentration on the mucosal and serosal sides at site 1 were comparable (Fig. 6) ; consequently, 5-FU was efficiently distributed to the mucosal side from the serosal side prior to distribution to the systemic circulation. These results suggest that the method of gastric serosal surface application of 5-FU could be applied to the chemotherapy of the both intramucosal cancer and intraserosal cancer in the stomach.
The low response rate of anticancer drugs against gastric cancer was suggested to be due to side effects induced by anticancer drugs before they were able to exert a significant anticancer effect; therefore, the side effects of anticancer drugs are important problems to overcome in cancer chemotherapy.
10) The common clinical systemic side effects of 5-FU are myelosuppression, stomatitis, nausea, emesis, and diarrhea after intravenous and/or oral administration, 11) and these might be caused by the high blood concentration and non-specific distribution of 5-FU. Accordingly, the blood concentration profiles of 5-FU after intravenous administration, oral administration, and gastric serosal surface application were evaluated as an index of the systemic side effects of 5-FU (Fig. 3) . After oral administration and the gastric serosal surface application of 5-FU, a low blood concentration (Ͻ4.4 mg/ml) was observed until 240 min. The maximum blood concentration of 5-FU after oral administration and gastric serosal surface application was markedly lower than after intravenous administration. After the gastric serosal surface application of 5-FU, the concentration of 5-FU in other tissues was significantly lower than that of site 1 in the stomach (Fig. 4C) . These results suggest that the gastric serosal surface application of 5-FU could diminish the systemic side effects during chemotherapy for gastric cancer, and accordingly, the administration doses of 5-FU could be increased for enhancing the anticancer effects.
The combined uses of various anticancer drugs by intravenous and oral administration were reported to enhance therapeutic effects against gastric cancer. [12] [13] [14] Therefore, the combination uses of other anticancer drugs with the applica- tion of 5-FU on the gastric serosal surface would be expected to enhance the therapeutic effects against gastric cancer.
Although the gastric arterial injection of anticancer drugs was studied to target the delivery of anticancer drugs to the stomach, 3, 4) it was difficult to remove the injected anticancer drugs while the serious side effects were occurring after administration. In contrast, the 5-FU that accumulated at site 1 after application on the gastric serosal surface was rapidly eliminated from site 1 after removal of the 5-FU in the cylindrical diffusion cell (Fig. 5) , suggesting that the interruption of the administration of anticancer drugs would reduce severe side effects immediately.
It has been reported that the intratumoral injection of anticancer drugs could enhance the potency of anticancer drugs by pharmaceutical modifications. 15) However, the direct injection of anticancer drugs poses safety concerns because of injury to organs by the needles and the administration volume limits, etc. As shown in Fig. 5 , the rapid elimination of 5-FU accumulated at site 1 suggested that even if 5-FU was directly injected into the stomach wall, it would be rapidly eliminated from the injected site. On the other hand, 5-FU was not only site-selectively, but also continuously, delivered to the stomach utilizing the absorption on the gastric serosal surface ( Fig. 2C; Fig. 6 ), suggesting the effectiveness of this administration method.
We previously reported that liver site-selective drug accumulation was enhanced by gradually and continuously instilling a small amount of drug solution on the liver surface in rats. 16) Recently, implantable infusion pumps have been developed for the treatment of several diseases, 17) and endoscopic and laparoscopic operation techniques have made marked progress. 18, 19) Furthermore, continuous ambulatory peritoneal dialysis is an extremely popular treatment modality for end stage renal failure; 20) consequently, the skilled catheter insertion into the intraperitoneal organs should be advanced in the future. It was reported that a collagen fleece coated with fibrin glue could be inserted on the liver and stomach by endoscopic surgery, 19) suggesting that proper pharmaceutics with drugs, which could achieve controlled drug release, could be applied to the gastric serosal surface by endoscopic surgery. Taking these findings into consideration, the application of suitable medical skill should make possible the clinical application of 5-FU to the gastric serosal surface.
In summary, we demonstrated the stomach-and site-selective delivery of 5-FU utilizing absorption on the gastric serosal surface in rats. Furthermore, 5-FU applied on the gastric serosal surface was efficiently delivered to the gastric mucosal side. The direct injection of drugs can injure organs with the needle; consequently, such treatment is limited in terms of injecting the drug continually. In contrast, the gastric serosal surface application does not stress the stomach, and therefore continuous administration may be possible to enable the long-term application of 5-FU. Thus, the stomachand site-selective delivery of 5-FU following application on the gastric serosal surface could be applied for clinical chemotherapy to the gastric cancer. Such information should be useful in the development of a novel administration method for anticancer drugs to targeted sites in the stomach.
